Cargando…
SMYD3 confers cisplatin chemoresistance of NSCLC cells in an ANKHD1-dependent manner
BACKGROUND: Cisplatin (DDP) remains the backbone of chemotherapy for non-small cell lung cancer (NSCLC), yet its clinical efficacy is limited by DDP resistance. We aim to investigate the role of the SET and MYND domain-containing protein 3 (SMYD3) in DDP resistance of NSCLC. METHODS: Expression patt...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Neoplasia Press
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027902/ https://www.ncbi.nlm.nih.gov/pubmed/33773404 http://dx.doi.org/10.1016/j.tranon.2021.101075 |